Skip to content
The Policy VaultThe Policy Vault

Brukinsa (zanubrutinib)Highmark

quantity limit exception

Initial criteria

  • additional quantities up to 8 capsules per day (80 mg) or up to 4 tablets per day (160 mg) may be approved when the member is taking a moderate CYP3A inducer

Approval duration

12 months